Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer

US10301685B2 · kind B2 · utility

Assignee

• Sividon Diagnostics GmbH · DE

Inventors

• Jan Brase · Cologne, DE
• Ralf Kronenwett · Cologne, DE
• Karin Fisch · Cologne, DE
• Mathias Gehrmann · Tönisvorst, DE
• Marcus Schmidt · Mainz, DE

Key dates

• Filing date: Oct 31, 2017
• Grant date: May 28, 2019
• Expiry date: Oct 31, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Described herein are methods for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. Said method includes the steps of determining the expression levels of the marker genes S100P and PCSK6 and mathematically combining the expression level values to yield a combined score and comparing said combined score to a reference-value, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen.